GSK plc has announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against ...

The China chief of AstraZeneca - Britain's biggest company - was arrested months ago, but his condition and whereabouts ...

The low-cost gym giant is coming off four consecutive months of higher foot traffic despite raising its signature membership price to $15 from $10 last summer. Galaxy Digital Sees Demand Surge as U.S.

In addition to obesity, modifiable risk factors include a low-quality diet (such as high consumption of processed meats, ...

Health-care companies fell as traders hedged their bets on the outlook for growth in the sector. Insurers, including Elevance, which recently warned of cost pressures from its Affordable Care Act ...

GlaxoSmithKline LLC (GSK) plans to lay off 150 Cambridge workers. The layoffs come months after GSK said it had planned to ...

Find insight on European pharmaceutical sector corporate bonds, GSK and more in the latest Market Talks covering Health Care.

GSK plc (NYSE:GSK) is one of the best cheap stocks under $50 to buy now. On July 15, BofA analyst Sachin Jain maintained a ...

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...